DR. ALBERTO BRONISCER, MD

Plain English
This study looked at brain tumors in patients with Noonan syndrome, a genetic condition. Out of 24 patients, 19 had Noonan syndrome, and 89% of them developed brain cancer, particularly low-grade tumors. Most of these tumors showed specific genetic changes, and some patients needed chemotherapy. This research is important because it helps doctors understand the risks of brain tumors in Noonan syndrome patients and may lead to new treatment options targeting their specific genetic issues. Who this helps: Patients with Noonan syndrome and their doctors.

Plain English
This study looked at the relationship between Noonan syndrome (NS) and certain types of brain tumors in 24 patients. It found that 79% of these patients had NS, and among those with NS, 89% developed brain tumors, primarily low-grade gliomas. This research is important because it highlights a significant link between NS and specific brain tumors, suggesting that new treatment strategies targeting certain genetic pathways could benefit these patients. Who this helps: Patients with Noonan syndrome and their doctors.

Plain English
This study looked at the immune cells called T cells in childhood brain tumors to understand how they can fight cancer. Researchers found that a higher level of diversity in the T cell receptors was linked to better outcomes for patients, indicating that patients with more diverse T cells may have a better chance of survival. The study also identified specific proteins on tumors that T cells can target, which could help develop more effective treatments. Who this helps: This research benefits pediatric cancer patients and their doctors by providing insights for better treatment options.

Plain English
This study focused on understanding high-grade gliomas (HGG), a type of brain tumor in infants and young children. Researchers analyzed 56 young patients and found that those with infant-type hemispheric glioma (IHG) had better survival rates—90.91% overall survival at five years—compared to other types of HGG, which had a much lower survival rate of just 16.67%. This research is important because it shows that not all high-grade gliomas are the same; understanding their differences can help tailor treatments for better outcomes and may allow for less aggressive therapy for some patients. Who this helps: This benefits young patients with brain tumors and their doctors.

Plain English
This study looked at gliomatosis cerebri (GC), a type of brain tumor that affects children and teenagers. Researchers analyzed data from 104 patients and found that the average survival time was only 15.5 months. The study also revealed that the type of tumor (grade) significantly influenced survival rates: patients with lower-grade tumors survived an average of 47.8 months, while those with the highest grade only lived about 10.4 months. Who this helps: This information is crucial for doctors and families making treatment decisions for children with diffuse gliomas.

Plain English
This study focused on a treatment called alisertib for children under 22 years old who have a rare and aggressive brain tumor known as atypical teratoid/rhabdoid tumor (AT/RT) that keeps coming back. Among 30 patients, about 30% had stable disease or better after 12 weeks, with a one-year survival rate of about 37%. Although the treatment did not achieve its initial goals, it was generally well tolerated, with most side effects being manageable. Who this helps: This helps young patients with recurrent AT/RT and their doctors looking for treatment options.

Plain English
This study looked at how changes in brain development are related to the spread of medulloblastoma (MB), the most common type of brain tumor in children. Researchers found that a molecule called SMARCD3 is involved in this process and helps the tumor spread by affecting certain signaling pathways. Specifically, when SMARCD3 is more active, it boosts the signaling that leads to tumor growth and spread, indicating that treating these tumors with drugs that target this pathway might be helpful. Who this helps: This research benefits patients with medulloblastoma and their doctors by providing new potential treatment options.

Plain English
This study looked at patients aged 10 years and older diagnosed with diffuse intrinsic pontine glioma (DIPG), a type of brain tumor. Out of 1,010 patients, 208 were over 10; their average survival after diagnosis was 13 months, with only 18 of them (about 11.8%) surviving longer than 2 years. The findings are important because they can help identify which older patients might have better outcomes, as those who survived longer tended to be older and had symptoms for a longer time before diagnosis. Who this helps: This helps patients and their families understand more about the characteristics and survival rates associated with DIPG in older children and young adults.

Plain English
This study looked at how effective a new imaging method called C-methionine PET is for spotting recurrence of high-grade brain tumors in children when MRI findings are unclear. The researchers tested this on 27 areas of concern in 26 patients and found that C-methionine PET was 100% sensitive, meaning it was able to correctly identify all actual tumor recurrences, while traditional MRI had lower accuracy rates. This is important because better detection of tumor recurrence can lead to more effective treatment decisions and improved outcomes for these young patients. Who this helps: Patients with pediatric high-grade gliomas.

Plain English
Researchers gathered at the seventh International RASopathies Symposium to discuss genetic disorders known as RASopathies, which impact how certain genes function in the body. They found promising progress in translating research into clinical treatments, including the use of new medications targeting the Ras/MAPK pathway, which could benefit patients with these conditions. This is a significant development because it means that patients may soon have access to effective therapies based on recent discoveries. Who this helps: Patients with RASopathies and their families.

Plain English
This research focused on a type of aggressive brain tumor called diffuse midline gliomas (DMGs) that have a specific genetic mutation known as H3K27M. The study found that these tumors rely heavily on an amino acid called methionine for growth, and a key enzyme, MAT2A, is crucial for methionine metabolism. By reducing MAT2A levels, the researchers observed that cancer cell growth was hindered, and mice on a methionine-restricted diet lived longer, highlighting MAT2A as a potential target for treatment. Who this helps: This benefits patients with H3K27M mutant gliomas and their doctors.

Plain English
This study focused on understanding rare brain tumors in children known as CNS embryonal tumors by analyzing the molecular characteristics of 70 patients from different clinical trials. The research found that survival rates varied significantly depending on the specific molecular type of the tumor, with patients having CNS neuroblastoma with FOXR2 activation showing 5-year survival rates of 83.3%, while those with high-grade neuroepithelial tumors showed poor responses to initial chemotherapy with a 5-year survival rate of just 53.6% after salvage treatment. This is important because it highlights the need for personalized treatment strategies based on the tumor's molecular profile, which can significantly influence patient outcomes. Who this helps: This research benefits doctors and healthcare professionals by providing critical insights for treating children with these rare tumors.

Plain English
This research looked at a group of rare brain tumors in children, specifically those with a type of genetic change called EWSR1-non-ETS fusions. The study found five cases of these tumors in young patients, with outcomes varying—two had favorable outcomes, and two had unfavorable outcomes—over a follow-up time of about 30 months. Understanding the specific genetic fusions in these tumors could help improve diagnosis and treatment. Who this helps: This research benefits pediatric patients with rare brain tumors and their doctors.

Plain English
This study looked at how different biological and genetic features affect treatment outcomes in children with a brain cancer called medulloblastoma. Researchers enrolled 330 patients aged 3 to 21 and found that those at average risk of disease spread had a five-year survival rate of 83.2%, while high-risk patients had a lower rate of 58.7%. The study identified distinct patient groups with varying risks, allowing for better tailored treatments in future trials. Who this helps: This helps young patients with medulloblastoma and their doctors by improving treatment strategies.

Plain English
This study looked at how different molecular groups of a rare brain cancer called atypical teratoid rhabdoid tumor (ATRT) affect survival rates in children. Out of 74 children treated, 32% were still alive after an average of about 8.4 years. The research found that infants with a specific group (ATRT-TYR) had the best survival rates, whereas those with metastases (spread of the cancer) had much poorer outcomes—only 25% of older children and none of the infants survived five years. Who this helps: This research benefits doctors and patients by providing insights into treatment strategies tailored to the molecular characteristics of ATRT.

Plain English
This study looked at how certain proteins in the immune system, specifically PD1 and TIGIT, affect treatment outcomes for patients with glioblastoma (a type of aggressive brain tumor). The researchers found that blocking both PD1 and TIGIT significantly improved survival in mouse models of glioblastoma, leading to better functioning of immune cells that attack tumors. This matters because it highlights a potential new way to enhance the effectiveness of treatments for glioblastoma patients, who currently have limited options. Who this helps: Patients with glioblastoma.

Plain English
Researchers developed 21 new models from actual pediatric high-grade glioma tumors to better understand how these cancers differ and how they respond to treatments. These models effectively replicate the characteristics of the original tumors, helping to uncover how different groups of tumors may respond to specific drugs. The study found that using these models can predict varied reactions to certain drug therapies, which is crucial for finding effective treatments. Who this helps: This helps doctors and researchers find better therapies for children with brain tumors.

Plain English
This study looked at how safe and effective a drug called crenolanib is for treating children and young adults with high-grade brain tumors, specifically a type called DIPG. Researchers found that the maximum safe dose of crenolanib was 170 mg/m², and while some patients experienced side effects like elevated liver enzymes and decreased blood cell counts, most tolerated the treatment well. Importantly, 25% of new DIPG cases and 30% of recurrent high-grade glioma cases showed genetic changes related to their tumors, which could help inform future treatments. Who this helps: This helps children and young adults affected by high-grade brain tumors.

Plain English
This study looked at how the drug high-dose methotrexate (HDMTX) works in infants and young children with brain tumors. Researchers analyzed the drug’s behavior in 178 patients and found that younger infants cleared the drug much slower compared to older children, but this didn’t lead to more side effects since they received lower doses. These findings are important because they help set more accurate dosing guidelines for young patients, aiming to minimize toxicity while maximizing treatment effectiveness. Who this helps: This helps doctors and healthcare providers in treating infants and young children with brain tumors.

Plain English
This study looked at how different sizes of radiation therapy target areas affect patients with a brain tumor known as diffuse intrinsic pontine glioma (DIPG). Researchers compared treatments for 105 patients, where some received a standard 1 cm margin and others received an extended margin of 2-3 cm. They found that there was no significant difference in survival or tumor progression between the two groups, with patients surviving an average of 7.6 months without progression and 11.3 months overall. Who this helps: This information helps doctors determine the best treatment approach for DIPG patients.

Plain English
This article discusses the use of the drug erlotinib and its breakdown product, OSI-420, in treating infants and children with primary brain tumors. The authors aim to correct a mistake in how they reported their funding sources. Understanding the effects and safety of these treatments is crucial for improving care for young patients with brain tumors. Who this helps: This helps children with brain tumors and their doctors.

Plain English
This study looked at a new treatment combining a drug called veliparib with radiation and another drug, temozolomide, in children newly diagnosed with a type of brain tumor called diffuse intrinsic pontine glioma (DIPG). The researchers found that, although the treatment was generally tolerated, it did not improve survival rates compared to older treatments, with only 37% of patients surviving for one year and just 5% at two years. This matters because DIPG is a difficult-to-treat tumor, and finding effective therapies is crucial for improving outcomes in these patients. Who this helps: This helps children with DIPG and their families.

Plain English
This study looked at how radiation therapy affects neurological symptoms in patients with a type of brain tumor called diffuse intrinsic pontine glioma (DIPG). Researchers found that most patients (over 50%) noticed symptom improvement after receiving about 20 Gy of radiation, and significant improvement in neurological symptoms was linked to longer survival times. Specifically, patients who improved in their cranial nerve symptoms had a better chance of living longer, with a 0.2-year increase in overall survival. Who this helps: This helps patients with DIPG and their families by showing the potential benefits of radiation therapy in managing symptoms and improving survival.

Plain English
Researchers studied medulloblastoma, the most common brain cancer in children, which still results in high rates of illness and death. They found that this type of tumor has varied characteristics based on four main groups, revealing differences in genetics and how the tumor behaves, making targeted treatment more promising. Understanding these differences is crucial for developing better, personalized treatments for young patients with this aggressive cancer. Who this helps: Patients with medulloblastoma and their families.

Plain English
Researchers studied a type of childhood brain tumor called bithalamic gliomas, which often have specific mutations in the EGFR gene. They found that these tumors have unique genetic features and respond well to targeted treatments, specifically tyrosine kinase inhibitors, with promising effects seen in four children treated so far. This research is important because it opens up new treatment options for a challenging and deadly tumor type. Who this helps: Patients with bithalamic gliomas.

Plain English
This study looked at a rare type of brain tumor in children called atypical diffuse intrinsic pontine glioma (aDIPG), which does not show the usual imaging traits of the more common type, typical DIPG. Researchers analyzed samples from 33 patients and found that 54.6% of the tumors were higher-grade, more aggressive tumors, while 36% had a specific genetic mutation (H3 K27M), which is linked to worse outcomes. The findings highlight that imaging alone is not reliable for diagnosing these tumors, and that surgical sampling is safe, giving important information for treatment and prognosis. Who this helps: This helps doctors and families of children with brain tumors by providing clearer diagnostic and treatment options.

Plain English
This study looked at a treatment called peginterferon alpha-2b for young patients with craniopharyngiomas, which are rare brain tumors that can be hard to remove through surgery. Out of 18 patients treated, 28.6% had some positive response to the treatment, with one lasting over three months, and the average time before the disease worsened was about 19.5 months. These findings are important because they offer a new, well-tolerated treatment option for patients who can't undergo surgery or have tumors that come back. Who this helps: This helps young patients with recurrent or hard-to-treat craniopharyngiomas.

Plain English
Researchers studied diffuse intrinsic pontine glioma (DIPG), a deadly brain cancer in children that has not seen improvements in survival rates. They found that over 80% of DIPG tumors have a specific genetic mutation and proposed strategies to improve long-term survival, including better enrollment in clinical trials, the use of advanced imaging techniques, and focusing on combination therapies that target the underlying genetic issues. These steps are crucial for developing more effective treatments to help children with DIPG live longer. Who this helps: Patients with DIPG and their families.

Plain English
This study looked at a type of brain tumor in children called diffuse intrinsic pontine glioma (DIPG) and how well a specific PET imaging technique using C-methionine can detect it. Out of 22 patients, 82% had C-methionine uptake in their tumors, with initial scans showing a 17.2% increase in tumor volume after treatment, but the imaging results didn't predict survival rates. Understanding how C-methionine imaging relates to tumor behavior is crucial for improving diagnostics and treatment planning for these challenging tumors. Who this helps: This helps doctors and pediatric patients with DIPG.

Plain English
This study researched a specific mutation, called H3 K27M, that is common in a tough brain tumor found in children called diffuse intrinsic pontine glioma (DIPG). The researchers found that reducing the presence of this mutation slowed down tumor growth significantly, resulting in a delay of tumor progression, which suggests that targeting this mutation could be an important approach in treating DIPG. This matters because it offers a new way to potentially increase survival and improve treatment options for pediatric patients with this aggressive cancer. Who this helps: This helps pediatric patients with DIPG and their families by providing hope for more effective treatments.

Plain English
This research paper investigates the different types of brain tumors in children, finding that they can be grouped into more specific categories based on their molecular characteristics. For example, tumors previously thought to be similar, like medulloblastomas and high-grade gliomas, actually have multiple subtypes with different treatment needs and outcomes. This is important because it means that doctors can develop more personalized treatments that could improve survival rates and quality of life for young patients. Who this helps: This helps children with brain tumors and their families by offering better treatment options.

Plain English
This study looked at whether Schimmelpenning syndrome, a rare condition, is linked to brain tumors. The researchers reported on a young boy with Schimmelpenning syndrome who developed multiple brain tumors called pilocytic astrocytomas, but tests showed that the usual gene changes associated with the syndrome were not present in his tumors. This is important because it highlights a potential connection between the syndrome and certain brain tumors, which could lead to better understanding and treatment options. Who this helps: This information can aid doctors and researchers in treating and understanding the risks for patients with Schimmelpenning syndrome.

Plain English
This study focused on diffuse intrinsic pontine gliomas (DIPG), which are aggressive brain tumors that currently have no effective treatments. Researchers discovered that a specific mutation in DIPG cells, called H3K27M, makes these tumors grow faster by activating a signaling pathway known as RAS. By targeting a related protein called ERK5, they found that they could slow down tumor growth and improve survival in mice with DIPG, suggesting new potential treatment options. Who this helps: This research benefits patients with DIPG and their families by pointing towards new therapeutic strategies.

Plain English
This study looked at how the drug erlotinib, used to treat children with brain tumors, behaves in the body and its safety. Researchers found that younger children (under 5) clear the drug from their system much faster than older children, with a clearance rate of 6.8 liters per hour compared to 3.6 liters per hour for older patients. The findings indicate that the drug is generally well-tolerated, with mostly mild side effects, and no need to change the dosage based on age or other patient characteristics. Who this helps: This research benefits pediatric patients with brain tumors and their doctors by providing important information on drug safety and dosing.

Plain English
This study looked at how safe and effective the drug dabrafenib is for children and adolescents with specific types of cancer that have a V600 mutation. Twenty-seven young patients were treated with dabrafenib for an average of about 1.5 years, and the drug was generally well tolerated, with no serious side effects noted. This research is important because it shows that dabrafenib can be used safely in young patients and helps to set the stage for future studies on its effectiveness in treating these cancers. Who this helps: This helps young cancer patients with specific mutations, their families, and oncologists.

Plain English
This study looked at how effective and safe a drug called dabrafenib is for children with a specific type of brain tumor called low-grade glioma that has a V600 mutation. Out of 32 patients treated, 44% showed a positive response to the treatment, and 85% remained free from disease progression after one year. These results show that dabrafenib can significantly help children with this type of brain tumor while being reasonably tolerated. Who this helps: This helps pediatric patients with V600 mutation-positive low-grade glioma and their doctors.

Plain English
In this study, researchers looked at how a special type of brain scan called DSC-MRI can help predict treatment outcomes in children with aggressive brain tumors. They found that for the 22 children studied, those whose tumors showed higher blood flow (specifically, a regional blood flow of 1.16 or above) at the six-month mark were more likely to experience disease progression. This information is important because it shows that DSC-MRI can help doctors determine which patients might not respond well to treatment sooner and could guide better treatment decisions. Who this helps: This helps doctors and medical teams in treating children with high-grade brain tumors.

Plain English
This study looked at children with low-grade brain tumors to understand why some of them die from the disease. Out of 87 children studied, the average age at diagnosis was about 7.7 years, and they lived for about 4 years after diagnosis before dying, often due to the tumors worsening. A surprising 66% of the deaths were linked to the progression of the cancer, highlighting the need for better support, including mental health care, for these young patients. Who this helps: This information is valuable for healthcare providers, especially those treating children with these tumors, as well as their families.

Plain English
Researchers studied the effects of a drug called capecitabine given in easy-to-take tablets along with radiation therapy in children aged 3 to 17 who were newly diagnosed with a type of brain tumor called diffuse intrinsic pontine glioma (DIPG). They found that after one year, only 7.21% of children treated with capecitabine had not seen their tumor progress, compared to 15.59% in a historical group that received standard treatment. This matters because it shows that capecitabine did not improve tumor progression for these young patients, highlighting the need for more effective treatments. Who this helps: This research helps patients and their families by providing important information about treatment options for DIPG.

Plain English
This study examined two rare types of aggressive tumors called atypical teratoid rhabdoid tumors (ATRTs) and extra-central nervous system malignant rhabdoid tumors (extra-CNS MRTs). Researchers found that 21 patients were diagnosed at an average age of just 0.6 years, with most tumors losing a specific gene expression tied to these cancers. The findings highlight that these tumors have different genetic features, which is essential for developing targeted treatments to improve the outlook for affected individuals. Who this helps: This helps patients with malignant rhabdoid tumors and their doctors by guiding potential new therapies.

Plain English
This research looked at how a usually harmless nerve sheath tumor became cancerous in a family with a genetic mutation called SMARCB1 that raises the risk for certain tumors. Over seven years, one adult family member's tumor changed from low-grade to malignant. Understanding this progression is important for proper genetic counseling and monitoring for other family members who might also carry the SMARCB1 mutation. Who this helps: This benefits patients with SMARCB1 mutations and their families.

Plain English
In this study, researchers tested a combination of two drugs, dasatinib and crizotinib, on 25 children with a type of brain cancer called high-grade diffuse intrinsic pontine glioma (DIPG). They found that while the maximum safe doses were dasatinib 50 mg and crizotinib 215 mg taken once daily, the treatment caused significant side effects like diarrhea and fatigue, and did not show meaningful benefits, as only two patients were able to stay on the treatment for at least six months. This lack of effectiveness and tolerability led researchers to conclude that this drug combination should not be tested further in children with this condition. Who this helps: This helps doctors and researchers by providing clear evidence on ineffective treatments for children with DIPG.

Plain English
This study looked at the differences between children and young adults who survive a long time (more than 2 years) and those who survive a shorter time (less than 2 years) after being diagnosed with diffuse intrinsic pontine glioma (DIPG), a type of brain tumor. Out of 1,008 patients, only 10% were long-term survivors, with a median survival of 11 months; however, 42% survived for at least one year. The researchers found that long-term survivors were often younger or older than 3 to 10 years old and received more aggressive treatment at diagnosis compared to short-term survivors, who more frequently showed signs of severe disease. Who this helps: This information benefits doctors and researchers working on improving treatment approaches for children with DIPG.

Plain English
This study looked at a special type of imaging called C-Methionine positron emission tomography (MET-PET) to see how well it can identify areas in the brains of children with aggressive brain tumors that are at high risk of coming back after treatment. Researchers examined 62 scans from 31 children and found that when a certain part of the tumor called non-contrast enhancing tumor (NCET) was more than 10% of the tumor, patients experienced a faster return of their cancer—about 5.8 months compared to 10.5 months for those with less NCET. These findings are important because they can help doctors predict cancer recurrence and improve treatment plans, especially for radiation therapy. Who this helps: This helps doctors treating children with high-grade gliomas and their families.

Plain English
This study looked at a 4-year-old boy diagnosed with a serious brain tumor called diffuse intrinsic pontine glioma (DIPG). After he received radiation treatment, new disease spread rapidly throughout his brain and spine, which was observed on MRI scans just three months later. This rapid spread highlights the aggressive nature of DIPG and the need for more effective treatments. Who this helps: This helps doctors and researchers better understand the progression of DIPG and guide treatment strategies for young patients.

Plain English
This study looked at how treatment for pediatric high-grade glioma (a type of brain cancer in children) fails and what that means for patient prognosis. Researchers followed 56 patients and found that 85.7% experienced tumor progression after treatment. The study revealed that central treatment failures were the most common at 42.6%, especially in patients who had only partial tumor removal, indicating a need to adjust treatment approaches based on how tumors respond. Who this helps: This helps doctors and researchers understand treatment outcomes better, leading to improved care for children with brain cancer.

Plain English
This study focused on children with a dangerous brain tumor called diffuse intrinsic pontine glioma (DIPG) who received expanded radiation treatment and additional therapy to block blood vessel growth. Among 55 children treated, 9 (or 39%) showed unusual brain changes after treatment, specifically in a trial where the treatment area was larger. These changes likely resulted from the combined effects of their age, the treatment, and the larger radiation exposure, which is important because it helps improve understanding of treatment side effects and may guide better future therapies. Who this helps: This helps doctors and researchers understand potential complications in young patients with DIPG.